NCT06713187Recruiting
Interleukin23 in Systemic Lupus
Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 27 Nov 2024
- Start date
- 1 May 2025
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- Sohag University
- Diseases
- Lupus (SLE)
- NCT number
- NCT06713187
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 May 2025 to the primary completion date, 1 Aug 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.
Who the study is looking for
- patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Hospital Coordinator of this site? Confirm its status | Sohag | Egypt | Recruiting |
| Sohag University Coordinator of this site? Confirm its status | Sohag | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.